(AGENPARL) – LONDON (UNITED KINGDOM), ven 18 giugno 2021 Opinion/decision on a Paediatric investigation plan (PIP): Fasenra,benralizumab, decision type: , therapeutic area: , PIP number: P/0314/2020

Fonte/Source: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip06-20